The FDA recently approved the use of an extended-release injectable formulation of the integrase inhibitor cabotegravir (CAB) for preexposure prophylaxis (PrEP) for adults and adolescents at risk for HIV infection. After two initial intramuscular (IM) injections given 1 month apart, it is administered every 2 months; it is the first non-oral PrEP therapy to become […]
Long-acting Injectable PrEP Approved: Cabotegravir Read More »
Given intracellular pharmacology differences, these preclinical models may be a conservative estimate of EFdA’s intracellular pharmacokinetics and efficacy in humans.
A Phase 2b, multicenter, open-label, rollover study.
Researchers used a widely published computer microsimulation model to examine the cost-effectiveness of long-acting injectable HIV PrEP compared to oral alternatives
Despite the high efficacy of pre-exposure prophylaxis (PrEP) in preventing HIV acquisition, PrEP uptake among Black cisgender women remains low. Our qualitative study assessed Black cisgender women’s perspectives, attitudes, and acceptability towards PrEP, in addition to exploring PrEP-related attitudes, facilitators, and barriers to PrEP access among health care staff.
Apretude (cabotegravir) is a long-acting injectable medication that can prevent HIV infection in people at risk for HIV exposure. Apretude is typically injected into the muscles of your buttocks every 2 months by a healthcare professional. Long-acting injectables can help improve medication adherence. And they are a great option if you don’t like daily pills.
FDA Approves Apretude: First Injectable Option for HIV Pre-Exposure Prophylaxis Read More »
Research scientists are working together to see if a combination of medications – lenacapavir and islatravir – can improve HIV management. Both of these medications have a big advantage over current antiretroviral therapy (ART): they can be taken once a week, rather than daily.
A Once-A-Week ART Trial with Lenacapavir and Islatravir Read More »
“We have to focus on making sure that this product is really going to the health facilities and to the people who really must get it and can use it.”
Injectable PrEP and COVID show we’re all in this together Read More »
Ongoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.
Lenacapavir: a first-in-class HIV-1 capsid inhibitor Read More »
For these patients and for others who contracted HIV infection with primary resistance, the subsequent iterative availability of new drug classes, including non-NRTIs and integrase-strand transferase inhibitors, essentially offered functional monotherapy against a background of complex . . .
Lenacapavir for HIV-1 — Potential Promise of a Long-Acting Antiretroviral Drug Read More »
